Searched for
ADVANCED PHARMACEUTICAL INTERMEDIATES
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- A flash of blue light just solved one of drug development's biggest puzzles, here's all about itScientists at the University of Münster report a major advance in light-powered chemistry for housane molecules on May 20, 2026. Using phot...
- From axles to rare earth: India draws up list of 100 products it still can't make enough ofIndia is set to boost its manufacturing sector by identifying around 100 products for domestic production. This initiative aims to reduce r...
- Why US stock market Dow Jones, S&P 500 and Nasdaq are surging big today: Dow jumps 350 points, Nasdaq jumps 250 points as Intel hits all-time high driving the rallyUS stock market surges today: why Dow Jones, S&P 500, and Nasdaq are rallying sharply despite global tensions? The Dow Jones Industrial Ave...
- Cohance Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surgeCohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Will the currency cycle help them? Yes, but very selectively: 10 pharma stocks with upside potential of up to 33%The biggest mistake made in currency cycles is to confuse revenue gain with pure earnings gain. A company may report stronger rupee revenue...
- Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facilityA groundbreaking ceremony led by Union Minister Jitendra Singh has marked the start of a new Rs 600 crore pharmaceutical manufacturing plan...
- Blue Jet Healthcare to invest Rs 2,300 crore in mega pharma facility in AndhraBlue Jet Healthcare is building a major pharmaceutical plant in Andhra Pradesh. The ₹2,300-crore facility will manufacture specialty chemic...
- This stock has generated 105.4% returns in 1 year. Why Ami Organics is the stock pick of the week for 4 analystsAmi Organics recorded robust growth in the December 2024 quarter. While its revenue increased by 65% year-on-year, adjusted PAT surged by 1...
- Blue Jet Healthcare IPO to open on October 25. Check detailsBlue Jet Healthcare IPO will run between October 25-27 with anchor investor allocation slated for October 23. The IPO is completely an offe...
- Cabinet approves foreign investment of up to Rs 9,589 crore in Suven PharmaThe Cabinet Committee on Economic Affairs has approved foreign investment of up to Rs 9,589 crore in Suven Pharmaceuticals by Cyprus-based ...
- SPC Life Sciences gets Sebi's go ahead to float IPOSPC Life Sciences has received approval from the Securities and Exchange Board of India (Sebi) to raise funds through an initial public off...
- CCI clears Berhyanda's acquisition of Suven PharmaThe acquisition is “by way of a share purchase agreement of December 26, 2022 and pursuant to the mandatory open offer in compliance with t...
- Ami Organics IPO to open on Sept 1; check price band and other detailsThe company has reduced its fresh issue size to Rs 200 crore from Rs 300 crore after fundraising of Rs 100 crore in a pre-IPO placement.
- Aarti Industries signs Rs 10,000 crore multi-year supply dealAarti Industries said it will invest USD 35-40 million to set up a dedicated large scale manufacturing facility for the production of this ...
- DRL on prowl overseas to scale up R&D optionsIndia’s largest drug maker, Dr Reddy’s Laboratories, is on the prowl for overseas acquisitions to scale up its custom pharmaceutical servic...
- Lupin acquires pharma business of RubaminDrug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
Load More
